All In Biotech

Drug Trial Radar · NCT07947966

Safety and Drug Concentrations of REGN20566 in Adults With Overweight or Obesity

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of REGN20566 in Adult Participants With Overweight or Obesity

Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 304 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

304

Planned (sponsor's estimate)

Start

Dec 14, 2026

Primary completion

Feb 2, 2028

Study completion Feb 2, 2028

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Nov 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will test a Regeneron drug called REGN20566 ("study drug") to see how safe it is and how participants with overweight or obesity respond to it. The study will be split into two parts, Part A and Part B. The study is looking at: * What side effects REGN20566 might cause * How much REGN20566 is in the blood at different times * If the body reacts to REGN20566 in a way that may cause REGN20566 to not work as well

Conditions

  • Overweight
  • Obesity

Interventions

  • REGN20566Drug

    Administered per the protocol

  • PlaceboDrug

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 16 weeks
  2. Severity of TEAEsTime frame: Up to 16 weeks
  3. Occurrence of TEAEsTime frame: Up to 27 weeks
  4. Severity of TEAEsTime frame: Up to 27 weeks

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.